Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 29Esophageal Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Carcinoma, Non-Small-Cell Lung 14Nasopharyngeal Carcinoma 12Head and Neck Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 8Oropharyngeal Neoplasms 8Lung Neoplasms 6Glioblastoma 6Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Carcinoma 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lymphatic Metastasis 2

Interventions

trilaciclib 1Observation 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myelosuppression × Chemoradiotherapy × Clear all
NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡